All-oral shorter treatment regimen for multidrug-and rifampicin-resistant tuberculosis (MDR/RR-TB): Evaluating its effectiveness, safety and impact on the quality of life of patients in Rwanda

Principal investigator: Yves Habimana Mucyo
Check PI profile

Investigators

Yves Habimana Mucyo, Patrick Migambi, Jean Claude Semuto Ngabonziza, Augustin Dushime

Study information

  • Research Area: TB
  • Research type: Longitudinal study
  • Start date: Jun 01, 2020
  • End date: Jun 30, 2024

Study aim of the objectives

The general objective of the study is to determine the effectiveness, safety, and impact on quality of life of all-oral shorter MDR/RR-TB regimens of 9/11-months duration under programmatic conditions.

Study setting/Area (Location)

Kabutare and Kibagabaga Hospitals

Implementing institution

RBC

Department/Division

TB&ORD & NRL

Impact on Policy

Findings from this study will inform national policy on TB program , and contribute to the evidence base and inform guidelines on MDR/RR-TB globally

Study implementation progress

Related research

None

Login
Support